Yan Shen

Yan Shen

Auto-generated profile, based on publicly available information

Yan Shen

Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2023 in Heliyon
Verified
Journal Article
Open access
CCChun Cao
Chun Cao
TWTeng Wang
Teng Wang
YLYun Luo
Yun Luo
YZYin Zhang
Yin Zhang
YDYue-Yu Dai
Yue-Yu Dai
YSYan Shen
Yan Shen
Acute myeloid leukemia (AML) is characterized by a high recurrence and mortality rate. Cuproptosis is involved in cell death regulation in in a variety of solid tumors. Long non-coding RNAs that regulate cuproptosis genes in the pathogenesis of acute leukemia have yet to be explored. First, cuproptosis genes with distinct expression levels were discovered by contrasting AML with normal samples from the TCGA and GTEx cohorts. Pearson correlation and univariate Cox-regression analysis were performed to identify cuproptosis-associated lncRNAs with significant prognostic values. Then the least absolute shrinkage and selection operator (LASSO) Cox regression was utilized to establish a multi-gene signature to predict AML prognosis. Next, Kaplan-Meier estimator, receiver operating characteristic curve, and a nomogram were performed to evaluate the predictive capacity of the risk signature. Functional enrichment analyses were employed to assess their function. Moreover, qRT-PCR testing of lncRNA expression in AML samples was conducted. The competing endogenous RNA (ceRNA) network was constructed to find the target genes. A risk model based on the signature of three cuproptosis-associated lncRNAs was developed. The results showed that the model possessed excellent prognostic potential. The nomogram raised the accuracy in predicting AML survival. In addition, functional enrichment analyses demonstrated an enrichment of inflammatory and immune-related pathways. Moreover, correlations between the risk signature and clinicopathological variables, tumor mutational burden, RNA stemness score, immune profile, and drug sensitivity were observed. Furthermore, we discovered that TRAF3IP2-AS1 may function as a ceRNA to regulate cuproptosis and ferroptosis gene expression. The risk signature established in this study could serve as a reliable biosignature for AML prognosis. And the findings presented here may facilitate research on cuproptosis in AML.

1 June 2010 in Chinese Journal of Integrative Medicine
Verified
Journal Article
Closed access
PDF file
HJHan Jiang
Han Jiang
YSYan Shen
Yan Shen
XWXiang-Gui Wang
Xiang-Gui Wang



1 January 2023 in Diseases & Research
Verified
Journal Article
Closed access
PDF file
CSCui Shaojuan
Cui Shaojuan
TXTan Xiaoyan
Tan Xiaoyan
DJDeng Jianchuan
Deng Jianchuan
YQYang Qing
Yang Qing
YJYao Jia
Yao Jia
SYShen Yan
Shen Yan